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abdominal and mediastinal lymphadenopathy, and 
pleural and peritoneal effusion. Biopsy of retroperi- 
toned lymph nodes showed non-caseating granulomas 
compatible with sarcoidosis, and oral predmsone was 
administered at 40 mg/day for about 6 months. In 
March 1996, due to progressive worsening of the 
patient’s general condition, he was again admitted to 
the hospital. Investigations revealed persistent hepato- 
splenomegaly, mediastinal and abdominal lymphade- 
nopathy with retroperitoneal mass, slight anemia 
(Hb=10.6 g%), microscopic hematuria, and CD4+ T- 
lymphocytopenia (CD4+= 105/m3) .  Immunoglobulin 
fractions were normal. Mantoux test was negative. 
Bone marrow biopsy showed granulomas not con- 
sistent with hematologic malignancy. The patient 
developed abdominal obstruction requiring surgery. 
Ziehl-Neelsen staining of intestinal biopsy showed 
numerous AFB. Chest X-ray revealed a miliary in- 
filtrate, and intravenous pyelogram demonstrated papil- 
lary necrosis. M. tuberculosis was cultured from intestinal 
biopsy and urine. Diagnosis of disseminated TB with 
involvement of chest, intestinal tract and kidney was 
made, and anti-TB therapy was started with isoniazid, 
rifampin, ethambutol and pyrazinamide. The isolate 
was susceptible to all anti-TB drugs. The patient 
obtained progressive clinical improvement. After 2 
years of anti-TB therapy and follow-up, the patient is 
doing well. However, CD4+ T-lymphocyte count was 
persistently low (Table 1, case 2). HIV laboratory tests 
were repeatedly negative (serology for antibodies to 
HIV-1 and HIV-2, and p24 antigen) as well as serologic 
tests for hepatitis B virus, hepatitis C virus, and 
Trepanemu pallidurn. 
These two cases of disseminated TB infections may 
be considered as a manifestation of ICL. The diagnosis 
of ICL is supported by the severe and persistent 
lymphocytopenia not fully explained by other causes. 
Our patients were neither HIV-infected nor 
affected by B-cell immunodeficiency or lymphoprolifer- 
ative disorders. It might be argued that TB may be the 
cause and not the consequence, of CD4+ T-lympho- 
cytopenia, but TB infection may cause transient, non- 
selective CD4’ T-lymphocytopenia, which is reversible 
with successhl treatment [3] .  Our patients presented 
selective and persistent depletion of CD4+ T- 
lymphocytes, despite effective anti-TB treatment. It 
might also be argued that steroid therapy could have 
contributed to the CD4+ T-lymphocyte depletion, at 
least in the patient receiving 6 months of treatment. 
However, steroid-induced CD4+ T-lymphocyte deple- 
tion is transient, reversible and accompanied by CD8+ 
T-lymphocyte depletion, without any alteration of the 
CD4/CD8 ratio [5]. Our patients have neither known 
exposure to TB, nor a history of previous TB illness. 
Corticosteroids were administrated erroneously only 
after illness manifestations, and may be considered an 
aggravating factor for TB manifestations, but not the 
cause of TB reactivation. 
Disseminated tuberculosis is a very rare manifest- 
ation of ICL: only one case has been described in a 
patient with previous Kaposi’s sarcoma [l]. In deahng 
with TB infection, underlying ICL should be con- 
sidered. TB may be included in the manifestations of 
ICL. 
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Urinary tract infections (UTIs) are among the most 
frequent bacterial infections in humans. Escherichia coli 
is, by far, the bacterium most commonly isolated in 
community-acquired UTI, varying according to series 
from 70% to 90%. Because of the high percentage of 
resistance to ampicillin and co-trimoxazole-approxi- 
mately 60% and 30% respectively [l]-found in the 
strains of E. coli isolated in our area, the fluoro- 
quinolones have become one of the first-choice 
therapies in the empirical treatment of UTI in Spain. 
Resistance to the quinolones in E. coli strains isolated 
in urine samples from out-patients has increased in 
C o r r e s D o n d e n c e  655 
Spain in recent years [l-31, as is beginning to occur in 
other countries [4]. As an example, our data for 1997, 
similar to those of other laboratories in our country, 
show 27.3% resistance to nalidixic acid and 16.0% to 
the fluoroquinolones in 2581 strains tested. 
In outpatients, many UTIs are treated empirically 
[5]  and, with the latest data, many physicians would 
question the use of the quinolones as empirical therapy. 
Nevertheless, the published susceptibility data are 
provided by microbiology laboratories, and should be 
interpreted bearing in mind the fact that many of 
the uncomplicated UTIs in outpatients are treated 
empirically so that neither the bacterium implicated 
nor their antibiotic susceptibility are ever known. 
In addition, almost all of the strains isolated in 
patients with complicated UTI, with reinfections or 
relapses, are isolated and their antibiotic susceptibilities 
are tested, since in these cases it is usual to request a 
urine culture. These strains are not necessarily repre- 
sentative of those found in the community. In our 
opinion, this would result in a distortion of the real facts 
concerning quinolone resistance in E. coli. 
In the Emergency Service of our hospital, nearly 
all UTIs treated are community acquired, and, in 
contrast with what occurs in the community, a urine 
culture is performed on the slightest suspicion of UTI. 
Also, in the Emergency Service we find a greater 
number of community-acquired complicated UTIs 
than are found in the general practitioner’s consulting 
rooms, which permits a statistical comparison of 
antibiotic susceptibility according to the type of UTI 
(complicated versus uncomplicated). E. coli accounts 
for the 78.3% of isolates from urine in this service 
during 1997. 
We studied the susceptibility of the E. coli iso- 
lated in patients with suspected UTI treated in the 
Emergency Service of our hospital and compared the 
pattern of resistance to quinolones and other antibiotics 
according to the type of UTI (complicated versus 
uncomplicated). 
All the isolates of E. coli obtained from urine 
cultures taken in the Emergency Service of our hospital 
on random days in 1997 and 1998 were studied. We 
obtained 125 strains from the same number of patients, 
all with community-acquired UTI. Clinical histories 
were reviewed and a protocol was completed for each 
patient. Reflected in the protocol, among other data, 
were: underlying disease, urinary tract pathology, prior 
episodes of UTI during the preceding year, signs 
and symptoms and the results of the urine analysis. 
According to the data obtained and following estab- 
lished criteria [6] it was decided in each case whether 
UTI was present or not and, if present, the form of 
presentation (acute uncomplicated cystitis, acute un- 
complicated pyelonephritis, recurrent UTI or compli- 
cated UTI). When the patients had a functionally, 
metabolically or anatomically abnormal urinary tract, 
or they were immunocompromised, complicated UTI 
was considered [6]. 
The antibiotic susceptibility of the E. coli strains 
was ascertained by broth microdilution with PASCO 
(Difco, Detroit, MI, USA). The results were inter- 
preted according to NCCLS criteria [7]. To compare 
antibiotic resistance in E. coli from complicated UTI 
and in E. roli from uncomplicated UTI, the two-tailed 
Fisher exact test was used. 
Of the 125 E. coli urine cultures, 69 were from 
women and 56 from men. All isolates obtained in men 
corresponded with complicated UTI. UTI could not 
be diagnosed in two of the women, and asymptomatic 
bacteriuria was considered. In the rest of the women, 
the UTI was classified as acute uncomplicated cystitis 
in 25 cases, acute uncomplicated pyelonephritis in 22, 
complicated UTI in 18 and recurrent UTI in two. 
Globally, there were 74 (59.2%) complicated UTIs, 49 
(39.2%) uncomplicated UTIs and two asymptomatic 
cases of bacteriuria. Of the 74 patients with com- 
plicated UTI, 16 (26.1%) had an anatomically abnormal 
urinary tract, 14 (18.9%) had renouretheral stones, 10 
(13.5%) were immunocompromised, six (8.1%) had 
diabetes mehtus, six (8.1%) had catheter-associated 
UTI, and six (8.1%) had been subjected to urinary tract 
surgery. In the remaining 16 (21.6%), no history of 
anatomic or structural anomalies was found and nor 
was there any underlying disease, but, since the patients 
were males, complicated UTI was considered. 
Of the 123 strains of E. coli causing UTI (exclud- 
ing the asymptomatic bacteriuria), 20 (16.26%) were 
resistant to nalidixic acid and 16 (13%) to norfloxacin 
and ciprofloxacin. However, of the 74 E. coli strains 
causing complicated UTI, 18 (24.32%) were resistant 
to nalidixic acid, while only two (4.08%) of the 49 
causing uncomplicated UTI were resistant (p=0.0025, 
Fisher exact test, two-tailed). Of the 74 E. coli strains 
isolated in complicated UTI, 16 (21.62%) were resistant 
to norfloxacin and ciprofloxacin, while none of those 
isolated in uncomplicated UTI was resistant to these 
antibiotics (p=0.00018, Fisher exact test, two-tailed). 
Resistances to ampicillin, cefazolin, gentamicin, co- 
trimoxazole and fosfomycin were also compared. There 
were no statistically significant differences. Table 1 
shows the total resistance and the resistance for each 
type of UTI to each of the antibiotics tested. 
In Spain, the annual consumption of quinolones, 
fundamentally fluoroquinolones, is high. In 1996, in a 
population of approximately 39 000 000 inhabitants, the 
consumption in outpatients was 4.87X lo6 units of 
fluoroquinolones (54% ciprofloxacin, 36% norfloxacin, 
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Table 1 Number of strains resistant to each of the antibiotics tested, in total and according to the type of UTI (complicated 
or uncomplicated) 
Antibiotic 
Total 
(n=123) 
Complicated UTI 
(n=74) 
Uncomplicated UTI 
(n=49) 
~~ 
Ampicillin 78 (63.41%) 49 (66.21%) 29 (59.18%) 
Fosfomycin 1 (0.81%) 0 1 (2.04%) 
Cefazolin 4 (3.25%) 3 (4.05%) 1 (2.04%) 
Co-nirnoxazole 25 (20.32%) 19 (25.67%) 6 (12.24%) 
Nalidixic acid 20 (16.26%) 18 (24.32%)a 2 (4.08%)" 
Gentamicin 6 (4.88%) 6 (8.11%) 0 
Norfloxacin 16 (13%) 16 (21.62%)" 0" 
Ciprofloxacin 16 (13%) 16 (21.62%)a 0" 
'p<0.05. 
10% others) [8]. Published data show a high incidence 
of fluoroquinolone resistance in E. coli isolated in urine. 
These figures have increased in recent years [l-31. 
Recent unpublished data, from both our laboratory and 
others, show up to 20% resistance to fluoroquinolone 
and up to 30% to nalidixic acid. Under these circum- 
stances many physicians may feel that the quinolones 
are losing ground in their role as empirical therapy for 
community-acquired UTI. However, when comparing 
the susceptibility to quinolones according to the type 
of UTI, significant differences are found. The data 
obtained in this study seem to indicate that the overall 
increase in quinolone resistance in E. coli is caused 
largely by the strains implicated in complicated UTI. 
The probable cause of these differences is prior treat- 
ment with quinolones which has brought about a 
selection of resistant strains. Patients with complicated 
UTI, since they have an underlying disease or structural 
or functional abnormalities of the urinary tract, are 
treated more often and for longer periods with anti- 
biotics. In Spain, since the late 1980s, these treatments 
have been carried out, in many cases, with fluoro- 
quinolones. Patients with uncomplicated UTI have, in 
general, received fewer and shorter prior treatments, 
with a lesser risk of selection of quinolone-resistant 
strains. For the physician, it is easier to determine the 
type of UTI than to ascertain prior antibiotic treat- 
ment, since patients, very often, do not remember. 
According to the type of UTI, one may deduce possible 
resistance patterns which influence the choice of 
empirical therapy. 
The high frequency of resistance reported in some 
works may be due to the bias caused by the use of 
strains isolated in the microbiology laboratory. These 
strains are usually the cause of all complicated UTI and 
only a proportion of those implicated in uncomplicated 
UTI, since in the latter case a urine culture is not always 
requested and empirical treatment is often preferred. 
It may be deduced from our results that, in Spain, 
the quinolones still constitute valid therapy for com- 
munity-acquired uncomplicated UTI. Judicious use of 
these antibiotics is advised to avoid the development of 
quinolone-resistant strains. However, in patients with 
complicated UTI, it is advisable to use the quinolone 
only when the result of the antibiogram is available. 
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